The US-based biotechnology company Novavax has tied up with the Serum Institute of India (SII) to manufacture its Covid-19 vaccine, namely Covovax. According to the company's claim, its nano-particle protein-based vaccine has demonstrated an overall 90.4 per cent efficacy in phase 3 clinical trials.from IndiaTV India: Google News Feed https://ift.tt/3wsugHI
via
No comments:
Post a Comment
Please do not enter spam link in the comment box. Suggestions are invited for improvement.